OncoMatch/Clinical Trials/NCT06365671
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Is NCT06365671 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Relmacabtagene autoleucel (relma-cel) for b-cell non hodgkin lymphoma.
Treatment: Relmacabtagene autoleucel (relma-cel) — Clinical trial for the safety and efficacy of CD19 CAR-T following autologous hematopoietic stem cell transplantation (ASCT) for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) with High-Risk Prognostic Factors
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: TP53 alterations
Presence of at least one of the following high-risk prognostic factors: (1) extranodal involvement; (2) maximum diameter of the bulky mass ≥5 cm; (3) TP53 gene alterations
Allowed: MYC rearrangement
high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement
Allowed: BCL2 rearrangement
high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement
Allowed: BCL6 rearrangement
high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody
individuals must have received anti-CD20 monoclonal antibody and anthracycline-containing chemotherapy regimen
Must have received: anthracycline
individuals must have received anti-CD20 monoclonal antibody and anthracycline-containing chemotherapy regimen
Cannot have received: autologous stem cell transplant
History of autologous or allogeneic stem cell transplantation
Cannot have received: allogeneic stem cell transplant
History of autologous or allogeneic stem cell transplantation
Cannot have received: CAR-T cell therapy targeting CD19
Prior chimeric antigen receptor cellular immunotherapy targeting CD19
Lab requirements
Kidney function
Serum creatinine ≤1.5 ULN, or creatinine clearance ≥ 30 mL/min
Liver function
ALT/AST ≤ 3 ULN; total bilirubin ≤1.5 mg/dL (<3x ULN in patients with Gilbert's syndrome, cholestasis due to hepatoportal compression adenopathy, biliary obstruction in patients with liver involvement or lymphoma)
Cardiac function
Cardiac ejection fraction ≥ 40%
Adequate renal and hepatic function defined as: Serum alanine aminotransferase (ALT/AST) ≤ 3 upper limit of normal (ULN); Total bilirubin ≤1.5 mg/dL(<3 times ULN in patients with Gilbert's syndrome, cholestasis due to hepatoportal compression adenopathy, biliary obstruction in patients with liver involvement or lymphoma); Serum creatinine ≤1.5 ULN, or creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min; Cardiac ejection fraction ≥ 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify